https://www.fiercebiotech.com/r-d/arqule-rises-on-renewed-hope-for-twice-damned-tivantinib
ArQule rises on renewed hope for twice-damned tivantinib | Fierce Biotech
Sep 27, 2013 - ArQule watched its shares scrape the bottom last fall when it pulled the plug on a late-stage lung cancer drug, but rumors that the Woburn, MA, company is...
renewed hoperises